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Werecentlyreported[J.LipidRes.42(2001),697;43(2002),1486;44(2003),716]thatb2-glycoprotein
I(b2GPI)formscomplexeswithoxidizedLDL(oxLDL)andautoantibodiesagainstthesecomplexesare
present in patients with SLE and antiphospholipid syndrome (APS). The relationship of b2GPI/oxLDL
complexes and IgG autoantibodies against b2GPI complexed with oxLig-1 (an oxLDL-derived ligand)
withclinicalmanifestations ofAPS was studiedin150APS andSLEpatients. The b2GPI/oxLDL levels
ofAPSpatientsweresimilartothoseofSLEpatientswithoutAPS,buttheyweresigniﬁcantlyhigherthan
healthy individuals. There was no difference in the complex levels among the patients with arterial,
venous thrombosis, or pregnancy morbidity. IgG anti-b2GPI/oxLig-1 levels of APS were signiﬁcantly
higher than those of SLE without APS and healthy individuals. Further, antibody levels of APS patients
with arterial thrombosis were signiﬁcantly higher than those patients with venous thrombosis and
pregnancy morbidity. Thus, oxidation of LDL leads the complexformation with b2GPIin SLE and APS
patients. In contrast, anti-b2GPI/oxLig-1 autoantibodies were generated only in APS and were strongly
associated with arterial thrombosis. These results suggest that autoantibodies against b2GPI/oxLDL
complexes are etiologically important in the development of atherosclerosis in APS.
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INTRODUCTION
High serum levels of antiphospholipid antibodies have
been associated with thromboembolic events of both the
arterial and venous vasculature, and with pregnancy
morbidity (miscarriages and fetal loss). These features are
major criteria for the classiﬁcation of the antiphospholipid
syndrome (APS), a clinical entity that may be present
in the context of a systemic autoimmune disorder
(secondary APS), or in the absence of an underlying
disease (primaryAPS) (Hughes etal.,1986;Gharavi etal.,
1987). Antiphospholipid antibodies, anti-cardiolipin anti-
bodies (aCL) or lupus anticoagulants, are a heterogeneous
group of autoantibodies with a possible pathogenic
role in the development of the clinical manifestations of
APS. These antibodies are characterized by their reactivity
to negatively charged phospholipids, phospholipid/
protein complexes, and certain proteins presented on
suitable surfaces (i.e. activated cell membranes,
oxygenated polystyrene) (Matsuura et al., 1994; Roubey,
1994).
Several plasma proteins that participate in coagulation
and interact with anionic phospholipids have been
described as antiphospholipid cofactors, i.e. b2-glyco-
protein I (b2GPI), prothrombin, and annexin V. These
protein cofactors have been shown to be relevant antigenic
targets for antiphospholipid antibodies (Matsuura et al.,
1990; McNeil et al., 1990). b2GPI is a 50kDa single-chain
polypeptide composed of 326 amino acid residues,
arranged in 5 homologous repeats known as complement
control protein domains. In vitro, b2GPI binds strongly to
anionic molecules, such as negatively charged phospho-
lipids, heparin, and lipoproteins, as well as to activated
platelets and apoptotic cell membranes. Further, b2GPI
has anticoagulant properties, as it has been shown to
inhibit the intrinsic coagulation pathway, prothrombinase
activity, and ADP-dependent platelet aggregation (Sheng
et al., 1998). It has also been reported to interact with
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system (Merrill et al., 1999). b2GPI’s ﬁfth domain
contains a patch of positively charged amino acids that
likely represents the binding region for phospholipids
(Bouma et al., 1999; Hoshino et al., 2000).
Venous thromboembolic complications represent the
mostcommonclinicalﬁndinginAPS patients(Harris etal.,
1986; Ginsburg et al., 1992; Bick and Baker, 1999).
However,over25% ofthepatients enrolledintoaEuropean
cohortof1000APSpatientspresentedanarterialthrombotic
event (myocardial infarction, cerebrovascular accident,
angina, etc.) as the initial clinical manifestation (Cervera
et al., 2002). More recently, the premature (or accelerated)
development of atherosclerosis has been recognized in
autoimmune patients (Ward, 1999; Aranow and Ginzler,
2000;vanDoornumetal.,2002).Thetraditionalriskfactors
for atherosclerosis failed to account for these changes
(Esdaile et al., 2001). Increased levels of autoantibodies
against oxidized low-density lipoprotein (oxLDL), phos-
pholipids, and Lp(a), have been proposed as alternative
mechanisms as well as certain biochemical and genetic
abnormalities (Lockshin et al., 2001). Oxidation of LDL
(oxLDL) plays an important pathogenic role in early events
leading to atherosclerosis (Berliner and Heinecke, 1996;
Steinberg,1997).oxLDLisapro-inﬂammatorychemotactic
agent for macrophages and T lymphocytes, which have a
central role in atherogenesis (McMurray et al.,1 9 9 3 ) .I n
addition, oxLDL has been found in human and rabbit
atherosclerotic lesions (Yla-Herttuala et al.,1 9 8 9 ) ,a n d
shown to be an immunogen producing autoantibodies in
patients with autoimmune disorders, such as systemic lupus
erythematosus(SLE)andAPS(Salonenetal.,1992;Vaarala
et al., 1993). The participation of the immune system in the
development of atherosclerosis is becoming apparent and
some antiphospholipid antibodies may also be possible
participants(Vaarala,1996;Romeroetal.,1998;Tinahones
et al.,1 9 9 8 ) .
b2GPI has also been localized in human atherosclerotic
lesions by immunohistochemical staining (George et al.,
1999), which suggests a role of b2GPI (and antipho-
spholipid antibodies, i.e. anti-b2GPI antibodies) in
atherosclerosis. In 1997, we (Hasunuma et al., 1997)
reported that Cu
2þ-oxLDL, unlike native LDL, binds to
b2GPI. Invitro macrophage uptake of oxLDL was slightly
decreased in the presence of b2GPI, as compared to
oxLDL alone. In contrast, the addition of an antiphos-
pholipid antibody, i.e. b2GPI-dependent aCL (or anti-
b2GPI), together with b2GPI, resulted in a signiﬁcant
increase of oxLDL uptake by macrophages. It is well-
known that oxLDL uptake by macrophages is inhibited
with polyinosinic acid, a scavenger receptor blocker.
However, the increased b2GPI and anti-b2GPI antibody
dependent uptake was not affected by polyinosinic acid
anditismostpossiblethatmacrophageFcgreceptorswere
involved in the binding. This mechanism may be relevant
tothedevelopmentofatherosclerosisinpatientswithAPS.
The b2GPI-speciﬁc ligand on the oxLDL particles
(oxLig-1, 7-ketocholesteryl-9-carboxynonanoate) respon-
sible for the oxLDL interaction with b2GPI has been
isolated and identiﬁed. Increased macrophage uptake of
liposomes (as a model of oxLDL) has also been reported
when oxLig-1/b2GPI/antibody complexes were applied
(Kobayashi et al., 2001; Liu et al., 2002). Most recently,
we have reported that oxidatively modiﬁed LDL interacts
in vivo with b2GPI, and detected b2GPI/oxLDL
complexes, autoantibodies against b2GPI/oxLig-1 com-
plexes, and IgG immune complexes containing b2GPI and
oxLDL in serum samples from SLE and APS patients
(Kobayahsi et al., 2003).
In the present study, serum levels of b2GPI/oxLDL
complexes and IgG anti-b2GPI/oxLig-1 autoantibodies
were measured in patients with APS, and their association
with clinical manifestations of APS was assessed.
Our results indicate that oxidation of LDL leads the
complex formation with b2GPI, and that these complexes
commonly appear in the blood stream of patients with
APS as well as in SLE patients with or without APS.
However, autoantibodies against b2GPI/oxLig-1 were
only generated in APS patients. Further, these antibodies
showed a stronger correlation with arterial thrombosis
when compared to venous thrombosis. These results
may indicate etiological importance of IgG anti-
b2GPI/oxLDL (oxLig-1) autoantibodies in the develop-
ment of atherosclerosis in APS patients.
MATERIALS AND METHODS
Patients
Serum samples from 150 patients were utilized in the
study. One hundred samples were obtained from APS
patients enrolled in the Registry for the APS (Oklahoma
Medical Research Foundation, Oklahoma City, OK—
www.slrapls.org).TheclinicaldiagnosisofAPSwasbased
on the Sapporo criteria for the classiﬁcation of APS
(Wilson et al., 1999). All patients had a positive lupus
anticoagulant and/or IgG b2GPI-dependent aCL ELISA
result on 2 or more occasions. Twenty-four patients were
classiﬁed as primary APS and 76 as secondary APS to
SLE.Eighty-eightoftheAPSpatientswerefemalesand12
males. The mean age was 44.6 years (range 18–82 years).
A separate population of 50 patients meeting the 1982
ACR criteria for SLE (Tan et al., 1982), with no history
of antiphospholipid antibodies, was used as control. In
addition, 43 serum samples from healthy blood bank
donors were also included in this study as controls.
Three major clinical manifestations for APS were
recorded: venous thrombosis, arterial thrombosis and
pregnancy morbidity. Venous thrombotic events included
deep-vein thrombosis (DVT), pulmonary embolism (PE)
and superﬁcial phlebitis conﬁrmed by Doppler ultrasound,
venography or ventilation–perfusion scanning. Arterial
thrombotic events included myocardial infarction (MI),
cerebrovascular accident (CVA) or peripheral arterial
thrombosis.Pregnancymorbiditywasevaluatedseparately,
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late pregnancy complications as previously deﬁned
(Wilson et al., 1999). Fourteen of the APS patients
had a history of thrombocytopenia (platelet count
,100,000mm
3). In all cases, thrombocytopenia was
present in combination with at least one of the above
clinical manifestations, since the Sapporo criteria were
used. The clinical characteristics and classiﬁcation of the
APS patients studied are summarized in Table I.
The Registry for the APS has been approved and moni-
toredbytheInternalReviewBoards(IRB)oftheOklahoma
Medical Research Foundation, New York University
Medical Center and (previously) Saint Luke’s-Roosevelt
Hospital Center in New York City. Informed consent was
given to all participants according to FDA/ICH guidelines
andinstitutionalrequirements.Thecurrentprojectwaspre-
approved by the Registry Advisory Board. A material
transfer agreement and inter-institutional assurances were




complex and anti-b2GPI/oxLig-1 antibodies: WB-CAL-1
monoclonal antibody reactive to b2GPI (IgG2a, k) derived
from a NZW x BXSB F1 mouse, a spontaneous model of
APS (Hashimoto et al., 1992), and EY2C9 monoclonal
anti-b2GPI antibody (IgM) established from peripheral
bloodlymphocytesofAPSpatients(Ichikawaetal.,1994).
Both monoclonal antibodies bind only to b2GPI com-
plexed with Cu
2þ-oxLDL and negatively-charged phos-
pholipid, such as CL and phosphatidylserine, but not to
monomeric (free) b2GPI in solution. 1D2 (Yamasa
Corporation, Choshi, Japan) is an IgG murine monoclonal
antibody speciﬁc for human ApoB-100 and the antibody
binding is not affected by the oxidation of LDL.
Puriﬁcation of Human b2GPI
Human b2GPI was puriﬁed from fresh normal plasma as
previously described (Finlayson and Mushinski, 1967)
with slight modiﬁcations. Brieﬂy, human plasma was
ﬁrst precipitated with 70% perchloric acid, extensively
dialyzed against Tris/NaCl buffer (pH 8.0) and concen-
trated before loading into a heparin column (Amersham
Biosciences, Piscataway, NJ). Pooled b2GPI fractions
were again dialyzed against sodium acetate/NaCl buffer
(pH 4.8) and concentrated. This preparation was then
loaded into a CM cellulose column (Sigma-Aldrich,
St. Louis, MO) and b2GPI fractions were pooled, dialyzed
against sodium acetate/NaCl buffer, concentrated at
approximately 1mg/ml and stored at 2708C until use.
The reactivity of b2GPI was checked by ELISA and the
purity was assessed by SDS-PAGE.
LDL Puriﬁcation and Oxidation
LDL was isolated by ultracentrifugation of fresh normal
human plasma in EDTA/KBr solutions as described
(Havel et al., 1955). LDL (d ¼ 1.019–1.063g/ml) was
adjusted to a concentration of 100mg/ml based on protein
concentration. The LDL fraction was oxidized with 5mM
CuSO4 in 10mM phosphate buffer containing, 150mM
NaCl, pH 7.4 (PBS) at 378C for 12h. Oxidation was
terminated by the addition of EDTA (at a ﬁnal
concentration of 1mM), and extensively PBS containing
EDTA. The degree of oxidation was measured using the
thiobarbituric acid reactive substance (TBARS) procedure
(Ohkawa et al., 1979).
ELISA Procedure for b2GPI/oxLDL Complexes
In the present study, the ELISA for b2GPI/oxLDL
complexes was performed in the presence of b2GPI to
ensure the detection of all possible forms of oxLDL.
oxLDL is predominantly present as a complex with b2GPI
but it may be present as free oxLDL. Monoclonal antibody
against complexed b2GPI (WB-CAL-1) was coated onto
96-well microtiter plate (Immunlon 2HB, Dynex Tech-
nologies Inc., Chantilly, VA) by incubating 50ml/well
of 5mg/ml of WB-CAL-1 in PBS, pH 7.4, overnight at
2–48C. The plate was blocked with PBS containing 1%
non-fat dry milk (nfdm) for 1h. Fifty microliters of
30mg/ml of human b2GPI in PBS was added to each well,
followed by 50ml of the serum samples diluted at 1:25 in
PBS-nfdm, and incubated for 2h at room temperature.
The wells were washed 4 times with PBS containing
0.05% Tween-20 between each step. Biotinylated 1D2
(anti-human ApoB-100) antibody diluted in PBS-nfdm
was added to the wells and incubated for 1h at room
temperature, followed by horseradish peroxidase (HRP)-
streptavidin. Color was developed with tetramethyl-
benzidine (TMB)/H2O2 and the reaction was stopped
with 0.36N sulfuric acid. Optical density was measured at
450nm. Serum oxLDL concentration (indicated as U/ml)
was calculated as a complex with b2GPI, against a
reference curve built with 2-fold serial dilutions of a
known concentration of oxLDL added to wells containing
b2GPI. The unit value was arbitrarily derived from the
concentration of the material used in the reference curve.
TABLE I Patients’ clinical characteristics
Patients n
Primary APS 24
Secondary APS (to SLE) 76





Arterial thrombosis only 31
Arterial + venous thrombosis 14
Venous thrombosis only 40
Pregnancy morbidity only 15
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23U/ml by testing 43 samples from healthy blood donors
(mean þ 3 standard deviations).
ELISA for IgG Anti-b2GPI/oxLig-1 Antibodies
TheELISAprocedureusedinthestudyhasbeenpreviously
described by Kobayashi et al. (2001) with slight
modiﬁcation. Fifty microliters of 100mg/ml of oxLig-1
(7-ketocholesteryl-9-carboxynonanoate) in ethanol was
coated onto Immunlon 2HB plates by evaporation.
The synthesis and characterization of oxLig-1 has been
recently reported(Kobayashi etal.,2001; Liuetal.,2002).
The plate was blocked with 1% BSA for 1h at room
temperature and washed. Fifty microliters of 30mg/ml of
human b2GPI in PBS containing 0.3% BSA was added to
theoxLig-1coatedwellstoallowcomplexformation.Fifty
microliters of serum or plasma samples diluted 1:100 in
PBS containing 0.3% BSA were subsequently added to the
wells and incubated for 1h at room temperature. The wells
were washed 4 times with PBS containing 0.05%
Tween-20 between steps. Diluted HRP-conjugated anti-
human IgG antibody was added to the wells and incubated
for 1h. Color was developed with TMB/H2O2 and the
reaction stopped with 0.36 N sulfuric acid. Optical density
was measured at 450nm. To establish the initial
performance of the assay and to select a strong reactive
sample to be used as control, monoclonal antibody,
EY2C9, and HRP-conjugated anti-human IgM antibody
were used. Level of IgG anti-b2GPI/oxLig-1 antibodies in
samples (expressed in U/ml as deﬁned above) was
calculated against the curve prepared with a selected
serumpositivesample.Anormalcut-offvaluefortheassay
was established at 10U/ml by testing 43 samples from
healthy blood donors (mean þ 3 standard deviations).
ELISA for aCL and Anti-b2GPI Antibodies
All APS samples were tested for IgG aCL and anti-b2GPI
antibodies on commercially available ELISA test kits
(Corgenix Inc., Westminster, CO), following the manu-
facturer’s instructions. The aCL ELISA test uses
exogenous bovine b2GPI thus measuring b2GPI-depen-
dent antibodies. The anti-b2GPI ELISA test uses puriﬁed
human b2GPI as antigen in the absence of exogenous
phospholipids.
Statistical Analysis
Statistical analysis was performed with a SigmaStat
program (SPSS Science Inc., Chicago, IL). Student’s t test
was performed to compare the results between different
groups and Chi-square test was used to assess the relation-
ship between antibodies and clinical manifestations.
Sensitivity, speciﬁcity, positive predictive value (PPV)
and odds ratio of anti-b2GPI/oxLig-1 antibodies were
calculated by 2 £ 2 contingency table analysis. Ninety-
ﬁve percent conﬁdence intervals for odds ratios were also
calculated. Pearson’s product moment correlation was
performed to assess the association of individual values
between variables. A p value of 0.05 or less was
considered as signiﬁcant.
RESULTS
Serum Levels of b2GPI/oxLDL Complexes
Figure 1 shows that most APS patients had elevated serum
levels of b2GPI/oxLDL complexes with a mean level of
96.7 ^ 72.3U/ml, while none of the healthy controls
reacted above the cut-off (mean 12.4 ^ 3.7U/ml,
p ¼ 5:8 £ 1029). The mean complex level of 24 primary
APS patients was 105.3 ^ 84.1U/ml, similar to the mean
of 76 patients with secondary APS to SLE
(93.9 ^ 68.5U/ml) and the mean level of 50 SLE patients
without APS (88.5 ^ 76.1U/ml). The mean complex level
for each APS subgroup was not statistically different:
98.9 ^ 75.4U/ml for arterial thrombosis ðn ¼ 45Þ;
91.3 ^ 57.7U/ml for venous one ðn ¼ 40Þ and
104.2 ^ 98.3U/ml for pregnancy morbidity ðn ¼ 15Þ:
However, the mean complex level of 31 patients with
arterial thrombosis only was 83.6 ^ 64.3U/ml, signiﬁ-
cantly lower ðp ¼ 0:039Þ; as compared with the mean
level of 14 patients with both arterial and venous
thrombosis (132.8 ^ 88.9U/ml). These results indicate
that oxidation of LDL leads the complex formation with
b2GPI and the complexes commonly appear in APS
patientsandSLEpatientswith/orwithoutAPS.Inaddition,
b2GPI/oxLDL complexes were particularly high in a
subgroup with apparent increased vasculopathy as
evidence by both arterial and venous thrombotic history.
Serum IgG Anti-b2GPI/oxLig-1 Antibodies
Thirty-sixpercentoftheAPSpatientshadelevatedlevelsof
IgG anti-b2GPI/oxLig-1 antibodies with a mean level of
22.5 ^ 64.9U/ml, signiﬁcantly higher as compared with
SLE patients without APS (9.1 ^ 5.1U/ml, p ¼ 0:02)a n d
to healthy controls (5.7 ^ 1.4U/ml, p ¼ 0:005). There was
no difference between primary and secondary APS
with regard to the antibody levels. The mean IgG anti-
b2GPI/oxLig-1 level of each subgroup was: 23.4 ^ 41.9
U/mlforarterialthrombosisðn ¼ 45Þwith40%classiﬁedas
positive, 12.3 ^ 16.5U/ml for venous ðn ¼ 39Þ with 36%
positives, and 8.6 ^ 6.3U/ml for pregnancy morbidity
ðn ¼ 15Þ with 20% positives (Fig. 2). The mean level of the
venousthrombosisðp ¼ 0:05Þandthepregnancymorbidity
ðp ¼ 0:01Þ subgroups were statistically lower as compared
with that of arterial thrombosis subgroup. These results
indicate signiﬁcantly higher serum levels of IgG anti-
b2GPI/oxLig-1 antibodies in primary and secondary APS
patients as compared with SLE patients without APS and
healthy controls. In addition, APS patients with a history of
arterial thrombosis had signiﬁcantly higher antibody levels,
D. LOPEZ et al. 206as compared with patients with venous thrombosis or
pregnancy morbidity.
Relationship of IgG Anti-b2GPI/oxLig-1 Antibodies
with aCL and Anti-b2GPI Antibodies
Due to the prominent presence of b2GPI in the antigenic
mixture used to detect IgG anti-b2GPI/oxLig-1 antibodies,
the relationship of these antibodies with b2GPI-dependent
antiphospholipid antibodies was evaluated. Figure 3
basically shows a good correlation of IgG anti-b2GPI/
oxLig-1 antibodies with (A) IgG aCL, and (B)
with anti-b2GPI antibodies in 100 APS patients ((A)
r ¼ 0:832; p , 0.001 and (B) r ¼ 0:688; p , 0.001,
respectively). However, The graph on the relationship of
FIGURE1 Serumlevels of b2GPI/oxLDLcomplexesmeasured by ELISAin healthy controls, SLE without clinical or serologic manifestations of APS
(diseased controls), and 100 APS patients classiﬁed into groups according to their history of arterial thrombosis, venous thrombosis or pregnancy
morbidity. The cut-off (horizontal broken line) was established at 23U/ml (mean þ 3 standard deviations from 43 healthy subjects). The horizontal solid
lines indicate the mean b2GPI/oxLDL level of each group.
FIGURE 2 Serum levels of IgG anti-b2GPI/oxLig-1 antibodies measured by ELISA in healthy controls, SLE without clinical or serologic
manifestations of APS (diseased controls), and 100 APS patients classiﬁed into groups according to their history of arterial thrombosis, venous
thrombosis or pregnancy morbidity. The cut-off (horizontal broken line) was established at 10U/ml (mean þ 3 standard deviations from 43 healthy
subjects). The horizontal solid lines indicate the mean IgG anti-b2GPI /oxLig-1 antibody level of each group.
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showed a little dislocating distribution pattern. This
pattern may suggest the presence of distinct populations of
antibodies, some are much reactive for b2GPI directly and
others are to b2GPI/oxLig-1. Twelve (27%) of the APS
patients in the arterial thrombosis subgroup had antibodies
reacting to both b2GPI and b2GPI/oxLig-1, while only 4
(10%) in the venous thrombosis and none in the pregnancy
morbidity groups had this dual reactivity.
In comparing the arterial, venous and pregnancy
morbidity subgroups, the correlation between IgG anti-
b2GPI/oxLig-1 antibodies with IgG aCL, and between
IgG anti-b2 GPI/oxLig-1 anitbodies and IgG anti-b2GPI
antibodies was strongest in the arterial thrombosis
(r ¼ 0:807 and r ¼ 0:629 respectively), as compared
with the venous thrombosis (r ¼ 0:760 and r ¼ 0:559)
and the pregnancy morbidity subgroups (r ¼ 0:038 and
r ¼ 0:134). Thus, IgG anti-b2GPI/oxLig-1 antibodies
FIGURE 3 Correlation between IgG anti-b2GPI/oxLig-1 antibodies and antiphospholipid antibodies determined by ELISA in 100 APS patients.
(A) IgG anti-b2GPI/oxLig-1 antibodies versus IgG anticardiolipin antibodies (aCL); (B) IgG anti-b2GPI/oxLig-1 antibodies versus IgG anti-b2GPI
antibodies. The straight line represents the best-ﬁt linear regression.
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antibodies that are particularly associated with arterial
thrombosis.
Comparative Clinical Performance
The clinical performance (relative sensitivity and positive
predictive value—PPV) of IgG anti-b2GPI/oxLig-1
antibodies for the history of thrombosis (arterial and
venous) and pregnancy morbidity in APS patients was
evaluated by 2 £ 2 contingency table analysis. Table II
shows that IgG anti-b2GPI/oxLig-1 antibodies were
38.6% sensitive for total thrombosis (arterial and venous
combined) with a PPV of 94% ðp ¼ 0:001Þ: The
speciﬁcity of this antibody for total thrombosis was
93.7%. The PPV for arterial thrombosis was 90% and for
venous thrombosis 88% (p ¼ 0:002 and 0.005, respect-
ively). The relative sensitivity for pregnancy morbidity
was 20% with a PPV of 60% ðp ¼ 0:309Þ: These results
indicate that IgG anti-b2GPI/oxLig-1 antibodies are found
predominantly in those autoimmune patients who have a
history of vasculopathy, with a stronger association for
arterial than venous thrombosis in patients with APS.
DISCUSSION
The cholesterol that accumulates in macrophage-derived
foam cells of atherosclerotic lesions is derived from
circulating lipoproteins, mainly LDL, but LDL must be
modiﬁed before it can induce foam cell formation (Ross,
1999). Oxidation of LDL is an effective mechanism that
modiﬁes LDL, increasing its macrophage uptake via
scavenger receptors and intracellular accumulation.
Several studies have demonstrated that atherosclerosis is
an inﬂammatory disease, involving the dysregulation of
cholesterol homeostasis by aberrant interactions between
lipid-modulating elements and mediators of inﬂammation
(Steinberg, 2002). Although the initiating inﬂammatory
factor(s) remain unknown, likely candidates include
oxLDL, immunological injury, homocysteine and infec-
tious agents. An active role of antibodies in this process
has been proposed (Virella et al., 2002) as recent
prospective studies have indicated that b2GPI-dependent
aCL or anti-b2GPI antibodies are associated with MI and
stroke in men (Vaarala, 1998; Brey et al., 2001).
Our results indicate that oxidation of LDL is a common
occurrence in APS and SLE patients without APS, and has
demonstrated the presence of circulating b2GPI/oxLDL
complexes in these patients (Fig. 1). Although it can be
hypothesized that this might be related to chronic
inﬂammation of the vasculature that occurs in auto-
immune patients, the mechanism(s) for the increased
oxidation of LDL found here are not known. b2GPI binds
to oxLDL, not to native LDL, possibly promoting
its clearance from circulation (Hasunuma et al., 1997)
and preventing thrombus formation. Circulating
b2GPI/oxLDL complexes have been implicated as
atherogenic autoantigens, and their presence may
represent a risk factor or an indirect but signiﬁcant
contributor for thrombosis and atherosclerosis (Kobayahsi
et al., 2003) in an autoimmune background. As numerous
interacting inﬂammatory, oxidative and coagulation
factors are thought to contribute to the development of
atherosclerosis, the oxidative modiﬁcation of LDL may
play a role in the initiation, progression and terminal
events in these vascular lesions (Ross, 1999).
The high-density lipoprotein (HDL)-associated enzyme
paraoxonase (PON) has anti-oxidant activity that protects
LDL from oxidation (Durrington et al., 2001). Decreased
PON activity has been reported in patients with high levels
of aCL (Lambert et al., 2000). Furthermore, IgG anti-
b2GPI antibodies have been associated with reduced PON
activity in SLE and primary APS patients (Delgado-Alves
et al., 2002). PON activity is also known to increase with
lipid-lowering drugs (Belogh et al., 2001; Senti et al.,
2001), and in one study, cholesterol-lowering statins
prevented the in vitro endothelial cell activation normally
induced by anti-b2GPI antibodies (Meroni et al., 2001).
Antioxidant treatment for 4–6 weeks has been observed to
decrease the titer of circulating aCL antibodies in SLE and
APS patients (Ferro et al., 2002). Vascular injury as seen
in autoimmune patients may affect PON activity or any
other anti-oxidant mechanism, triggering LDL oxidative
changes. Taken together, these ﬁndings provide additional
support to the hypothesis that oxidative stress plays an
important role in antiphospholipid antibody production
and development of thrombosis in APS.
The mean level of IgG anti-b2GPI/oxLig-1 antibodies
was highest in APS patients with arterial thrombosis
(Fig. 2). The coexistence of these autoantibodies with
b2GPI/oxLDL complexes, suggest that these two elements
interact perhaps forming circulating immune complexes.
This observation along with the increased macrophage
uptake of b2GPI/oxLDL complexes in the presence of
anti-b2GPI/oxLig-1 antibodies, provides a possible
TABLE II Association between IgG anti-b2GPI/oxLig-1 antibodies and thrombosis or pregnancy morbidity in APS patients
APS manifestation (n) Sensitivity (%) PPV (%) Chi-square (p) OR (95% CI)
Total thrombosis (85) 38.8 94.3 0.001 9.5 (2.1–42.5)
Arterial thrombosis (45) 40.0 90.0 0.002 10 (2.1–47.1)
Venous thrombosis (40) 37.5 88.2 0.005 9 (1.9–43.1)
Pregnancy morbidity (15) 20.0 60.0 0.309* 3.7 (0.5–25.3)
PPV, positive predictive value; OR, odds ratio; CI, 95% conﬁdence interval.
*not statistically signiﬁcant.
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sclerosis in autoimmune patients. Two groups (Zhao et al.,
2001; Kobayahsi et al., 2003) using similar assay systems
have recently shown increased serum levels of oxLDL and
antibodies to oxLDL in APS patients with history of
arterial thrombotic events. It is possible that APS patients
also present immune complexes (b2GPI/oxLDL/
antibody). The ELISA system used in this study seems
to detect only free (unbound) antibodies to b2GPI/oxLDL
(oxLig-1) complexes. Although preliminary, our results
suggest that IgG anti-b2GPI/oxLDL (oxLig-1) antibodies
may represent a distinct subset of antiphospholipid
antibodies and that they may coexist with other
antibodies. IgG anti-b2GPI/oxLDL (oxLig-1) antibodies
appear to be a useful serologic marker with high
speciﬁcity for APS and might possibly have a pathogenic
role in atherosclerotic risk in autoimmune patients.
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